Endece
ENDECE is dedicated to discovering and developing treatments that stop disease progression, restore function, and improve quality of life for patients suffering from neurodegenerative and inflammatory diseases. They focus on proprietary compounds that impact gene expression to address diseases such as Multiple Sclerosis, ARDS, Alzheimer's, Niemann-Pick disease, NMOSD, and ODS, with a pipeline including NDC-1308 and other therapeutics.
Industries
Nr. of Employees
small (1-50)
Endece
Mequon, Wisconsin, United States, North America
Products
NDC-1308 (lead small-molecule clinical development candidate)
A small-molecule therapeutic candidate developed to modulate gene expression in macrophages and oligodendrocyte progenitor cells to reduce inflammation and induce remyelination; intended for intranasal CNS delivery and inhalation for pulmonary indications.
NDC-1308 (lead small-molecule clinical development candidate)
A small-molecule therapeutic candidate developed to modulate gene expression in macrophages and oligodendrocyte progenitor cells to reduce inflammation and induce remyelination; intended for intranasal CNS delivery and inhalation for pulmonary indications.
Services
Small-molecule discovery and preclinical development
Discovery and preclinical advancement of small molecules that modulate gene expression for inflammatory, demyelinating, and metabolic diseases.
Formulation and route-of-administration development (intranasal and inhalation)
Design and development of delivery formulations and administration methods for targeting CNS via the olfactory epithelium and pulmonary delivery via nebulizer/inhalation.
Preclinical-to-IND enabling development
Execution of preclinical efficacy and safety studies and preparation for IND-enabling package and early-phase clinical studies; includes regulatory interactions such as pre-IND meeting with FDA.
Scalable small-molecule manufacturing
Process development and scale-up capability for small-molecule candidates to supply quantities required for expedited clinical studies.
Small-molecule discovery and preclinical development
Discovery and preclinical advancement of small molecules that modulate gene expression for inflammatory, demyelinating, and metabolic diseases.
Formulation and route-of-administration development (intranasal and inhalation)
Design and development of delivery formulations and administration methods for targeting CNS via the olfactory epithelium and pulmonary delivery via nebulizer/inhalation.
Preclinical-to-IND enabling development
Execution of preclinical efficacy and safety studies and preparation for IND-enabling package and early-phase clinical studies; includes regulatory interactions such as pre-IND meeting with FDA.
Scalable small-molecule manufacturing
Process development and scale-up capability for small-molecule candidates to supply quantities required for expedited clinical studies.
Expertise Areas
- Small-molecule drug discovery for neuroinflammatory and neurodegenerative disorders
- Preclinical translational development and animal modeling (EAE, cuprizone)
- Pulmonary inflammatory disease therapeutics and inhalation delivery
- Formulation development for intranasal and inhalation routes
Key Technologies
- Small-molecule therapeutics
- Gene-expression modulation via nuclear receptor activation
- Macrophage polarization assays (M1/M2 phenotyping)
- OPC differentiation and remyelination assays